218 related articles for article (PubMed ID: 37513897)
1. [
Chapeau D; Koustoulidou S; Handula M; Beekman S; de Ridder C; Stuurman D; de Blois E; Buchatskaya Y; van der Schilden K; de Jong M; Konijnenberg MW; Seimbille Y
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513897
[TBL] [Abstract][Full Text] [Related]
2. First preclinical evaluation of [
Handula M; Beekman S; Konijnenberg M; Stuurman D; de Ridder C; Bruchertseifer F; Morgenstern A; Denkova A; de Blois E; Seimbille Y
EJNMMI Radiopharm Chem; 2023 Jun; 8(1):13. PubMed ID: 37389800
[TBL] [Abstract][Full Text] [Related]
3. 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection.
Miao Y; Figueroa SD; Fisher DR; Moore HA; Testa RF; Hoffman TJ; Quinn TP
J Nucl Med; 2008 May; 49(5):823-9. PubMed ID: 18413404
[TBL] [Abstract][Full Text] [Related]
4. Targeted
Delpassand ES; Tworowska I; Esfandiari R; Torgue J; Hurt J; Shafie A; Núñez R
J Nucl Med; 2022 Sep; 63(9):1326-1333. PubMed ID: 34992153
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors.
Koustoulidou S; Handula M; de Ridder C; Stuurman D; Beekman S; de Jong M; Nonnekens J; Seimbille Y
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145375
[TBL] [Abstract][Full Text] [Related]
6.
King AP; Gutsche NT; Raju N; Fayn S; Baidoo KE; Bell MM; Olkowski CS; Swenson RE; Lin FI; Sadowski SM; Adler SS; Thiele NA; Wilson JJ; Choyke PL; Escorcia FE
J Nucl Med; 2023 Apr; 64(4):549-554. PubMed ID: 36396453
[TBL] [Abstract][Full Text] [Related]
7. A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice.
Zaid NRR; Kletting P; Winter G; Prasad V; Beer AJ; Glatting G
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959413
[TBL] [Abstract][Full Text] [Related]
8. Development and dosimetry of
Dos Santos JC; Schäfer M; Bauder-Wüst U; Lehnert W; Leotta K; Morgenstern A; Kopka K; Haberkorn U; Mier W; Kratochwil C
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1081-1091. PubMed ID: 30603987
[TBL] [Abstract][Full Text] [Related]
9.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
10. Influence of the Molar Activity of
Pretze M; Michler E; Runge R; Wetzig K; Tietze K; Brandt F; Schultz MK; Kotzerke J
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004470
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of
Banerjee SR; Minn I; Kumar V; Josefsson A; Lisok A; Brummet M; Chen J; Kiess AP; Baidoo K; Brayton C; Mease RC; Brechbiel M; Sgouros G; Hobbs RF; Pomper MG
J Nucl Med; 2020 Jan; 61(1):80-88. PubMed ID: 31253744
[TBL] [Abstract][Full Text] [Related]
12. Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate.
Chan HS; Konijnenberg MW; de Blois E; Koelewijn S; Baum RP; Morgenstern A; Bruchertseifer F; Breeman WA; de Jong M
EJNMMI Res; 2016 Dec; 6(1):6. PubMed ID: 26791386
[TBL] [Abstract][Full Text] [Related]
13. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
14. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
15. Imaging of
Kvassheim M; Tornes AJK; Juzeniene A; Stokke C; Revheim MR
EJNMMI Phys; 2023 Aug; 10(1):47. PubMed ID: 37603123
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry of [
Orcutt KD; Henry KE; Habjan C; Palmer K; Heimann J; Cupido JM; Gottumukkala V; Cissell DD; Lyon MC; Hussein AI; Liu D; Li M; Johnson FL; Schultz MK
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144563
[TBL] [Abstract][Full Text] [Related]
17. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
18. A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods.
Belli ML; Mezzenga E; Di Iorio V; Celli M; Caroli P; Canali E; Matteucci F; Tardelli E; Grassi I; Sansovini M; Nicolini S; Severi S; Cremonesi M; Ferrari M; Paganelli G; Sarnelli A
J Vis Exp; 2020 Apr; (158):. PubMed ID: 32391816
[TBL] [Abstract][Full Text] [Related]
19. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
20. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
